Compass Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Compass Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics focused on angiogenesis and immune-oncology. The filing covers the quarter and six months ended June 30, 2022, and was filed August 1, 2022. The company had 101.3 million common shares outstanding as of July 25, 2022.
Clinical-stage programs include CTX-009, CTX-471, and CTX-8371. The company has not generated product revenue and expects to remain dependent on external financing until potential commercialization.
Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $5.9 million | $10.3 million |
| General and administrative expense | $3.1 million | $5.9 million |
| Total operating expenses | $9.0 million | $16.2 million |
| Net loss | $8.5 million | $15.7 million |
| Net loss per share | $0.08 | $0.16 |
| Cash used in operating activities | Not separately provided | $12.5 million |
At June 30, 2022, cash and cash equivalents were $26.2 million, marketable securities were $105.8 million, and total cash, cash equivalents and marketable securities were approximately $132.0 million. Total assets were $140.3 million and total liabilities were $13.3 million. The company had no outstanding debt financing; liabilities primarily consisted of operating lease obligations, accounts payable and accrued expenses.
Accumulated deficit was $249.2 million. Unrealized losses on available-for-sale marketable securities were $0.5 million and were recorded in accumulated other comprehensive loss. The company reported no income tax expense for the six months ended June 30, 2022.
Material Changes Versus the Prior Comparable Period
- Second-quarter net loss decreased to $8.5 million from $55.8 million, primarily because the prior-year period included a $50.6 million in-process research and development charge related to the TRIGR acquisition.
- Six-month net loss decreased to $15.7 million from $63.2 million for the same reason.
- Research and development expense increased 102% in the quarter to $5.9 million and 35% for the six months to $10.3 million, driven primarily by higher manufacturing and clinical expenses.
- General and administrative expense increased 44% in the quarter to $3.1 million and 22% for the six months to $5.9 million, mainly due to higher stock-based compensation and personnel costs.
- Cash used in operating activities increased to $12.5 million from $11.5 million for the comparable six-month period.
- Investing cash outflows increased to $105.7 million, primarily because the company purchased $105.8 million of marketable securities. There were no comparable marketable-security purchases in the prior period.
- Interest income increased as a result of investments in marketable securities and higher interest rates. The prior-year interest expense related to a term loan that was extinguished in the fourth quarter of 2021.
Guidance, Outlook, Commentary, Risks and Unusual Items
- Management estimates that existing cash, cash equivalents and marketable securities will fund operating expenses and capital requirements into the second half of 2024 based on current plans. The company expects to require additional funding to complete development and pursue commercialization.
- For CTX-009, the company anticipated initiating a randomized Phase 2/3 trial in advanced biliary tract cancer in the third quarter of 2022 and a Phase 2 colorectal cancer trial in the fourth quarter of 2022. The proposed biliary tract cancer study would enroll 120 patients and compare CTX-009 plus paclitaxel with paclitaxel alone.
- Management stated that, based on preliminary data and regulatory discussions, it believed a biologics license application for CTX-009 could potentially be submitted in 2024. This timing remains preliminary and subject to clinical results, regulatory feedback, manufacturing availability and funding.
- In a South Korean CTX-009 study, preliminary data as of April 14, 2022 showed a 42% overall response rate and 92% clinical benefit rate among the reported evaluable population. The filing cautions that these data are preliminary and that formal safety analysis had not been completed.
- For CTX-471, dose-expansion cohorts were fully enrolled. The company reported a fourth preliminary partial response in July 2022, pending confirmation, and planned to complete the Phase 1b expansion study and begin a combination study with a PD-1 blocker in the fourth quarter of 2022, subject to regulatory feedback.
- For CTX-8371, GMP manufacturing was completed in the second quarter of 2022 after supply-chain delays. The company remained on track for an IND submission in the first quarter of 2023.
- COVID-19-related supply-chain delays have affected, and may continue to affect, clinical-trial manufacturing and timelines. Additional risks include clinical and regulatory failure, manufacturing constraints, competition, intellectual-property challenges, dependence on third parties and the need for additional capital.
- The company is obligated to pay ABL Bio a $6.0 million development milestone related to completion of Phase 1 for CTX-009. The milestone was recorded in accounts payable as of June 30, 2022.
- Future potential milestone payments under the Adimab agreement were approximately $2.0 million. Future expense and payment obligations under the Fujifilm statement of work were approximately $0.6 million.
- No material legal proceedings were reported. Management concluded that disclosure controls and procedures were effective as of June 30, 2022.
Most Important Facts for Investors to Verify
- Whether the company’s projected cash runway into the second half of 2024 remains achievable after planned CTX-009, CTX-471 and CTX-8371 activities.
- Actual initiation, enrollment, design and regulatory status of the proposed CTX-009 Phase 2/3 biliary tract cancer trial and colorectal cancer trial.
- Whether preliminary CTX-009 and CTX-471 response rates are confirmed in larger, controlled studies and whether safety findings support continued development.
- Timing of the CTX-8371 IND submission and any further manufacturing or supply-chain delays.
- Future financing requirements, potential shareholder dilution and the company’s ability to fund clinical development without materially reducing programs.
- Settlement and timing of the $6.0 million ABL Bio milestone and other contractual milestone, royalty and collaboration obligations.